Screener
Sarepta Therapeutics, Inc. SRPT PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Manufacturing-related deposits and prepaids | 48,454 | 113,455 |
| Other current assets | 105,784 | 171,856 |
| Total current assets | 2,223,824 | 2,537,938 |
| Property and equipment, net | 325,991 | 345,125 |
| Right of use assets | 120,847 | 125,495 |
| Non-current inventory | 226,333 | 184,543 |
| Non-current investments | 145,372 | 1,048 |
| Other non-current assets | 146,145 | 155,554 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s PP&E (net)?
- Sarepta Therapeutics, Inc. (SRPT) reported PP&E (net) of $325.99M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s PP&E (net) changed year-over-year?
- Sarepta Therapeutics, Inc.'s PP&E (net) decreased by 12.3% year-over-year, from $371.86M to $325.99M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s PP&E (net)?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s PP&E (net) has grown at a 12.6% compound annual growth rate (CAGR), from $190.43M to $345.13M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Sarepta Therapeutics, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude